NMTC CBO buys 1M shares, granted 500K options

NEUROONE MEDICAL TECHNOLOGIES Corp’s Chief Business Officer, David J. Wambeke, reported acquiring both stock options and common shares.

Rhea-AI Filing Summary

NEUROONE MEDICAL TECHNOLOGIES Corp’s Chief Business Officer, David J. Wambeke, reported acquiring both stock options and common shares. On March 1, 2026, he received an option to purchase 500,000 shares of common stock at an exercise price of $0.00 per share. According to the terms, 25% of this option will vest on March 1, 2027, with the remaining 75% vesting in 12 equal quarterly installments starting March 31, 2027. On the same date, he also made an open-market purchase of 1,000,000 shares of common stock at a price of $0.6704 per share, bringing his directly owned common stock position to 1,000,000 shares.

Insights

Equity compensation and governance analyst

Insider increases direct ownership and receives sizable option grant.

David J. Wambeke, the Chief Business Officer of NEUROONE MEDICAL TECHNOLOGIES Corp, received a grant of options for 500,000 shares at an exercise price of $0.00. The vesting starts on March 1, 2027 with a standard quarterly schedule thereafter.

He also purchased 1,000,000 common shares on the open market at $0.6704 per share, increasing his directly held stake to 1,000,000 shares. While these moves show a larger personal position, the overall impact depends on the company’s total share count and broader ownership structure, which are not detailed in this excerpt.

Insider Trade Summary

Net Buyer: 1,000,000 shares

Net Buy 2 txns

Insider Wambeke David J.

Role Chief Business Officer

Bought 1,000,000 shs ($670K)

Type	Security	Shares	Price	Value
Grant/Award	Option to Purchase Common Stock	500,000	$0.00	$0.00
Purchase	Common Stock	1,000,000	$0.6704	$670K

Holdings After Transaction: Option to Purchase Common Stock — 500,000 contracts (Direct); Common Stock — 1,000,000 shares (Direct)

Footnotes (1)

1. F1. 25% will vest on March 1, 2027, and the remaining 75% will vest in 12 equal installments on the last day of each quarter beginning on March 31, 2027.

FAQ

What insider transactions did NMTC’s David J. Wambeke report?

David J. Wambeke reported two transactions on March 1, 2026: a grant of options for 500,000 shares at a $0.00 exercise price and an open-market purchase of 1,000,000 common shares at $0.6704 each, all held directly.

How many NMTC options were granted to David J. Wambeke and at what price?

He was granted options to purchase 500,000 shares of NEUROONE MEDICAL TECHNOLOGIES common stock at an exercise price of $0.00 per share. These options vest over time beginning in March 2027, reflecting long-term equity compensation rather than an immediate cash transaction.

What is the vesting schedule for David J. Wambeke’s 500,000 NMTC stock options?

Twenty-five percent of the 500,000-share option grant will vest on March 1, 2027. The remaining 75% vests in 12 equal installments on the last day of each quarter, starting March 31, 2027, creating a multi-year vesting period tied to continued service.

How many NMTC common shares did David J. Wambeke buy on the open market?

He purchased 1,000,000 shares of NEUROONE MEDICAL TECHNOLOGIES common stock in an open-market transaction. The shares were acquired at a price of $0.6704 per share, resulting in a directly owned common stock position of 1,000,000 shares after the transaction.

What is David J. Wambeke’s direct common stock ownership in NMTC after these transactions?

Following the March 1, 2026 open-market purchase, David J. Wambeke directly owns 1,000,000 shares of NEUROONE MEDICAL TECHNOLOGIES common stock. This figure reflects his non-derivative holdings and is separate from the 500,000-share stock option grant reported the same day.

Are David J. Wambeke’s NMTC transactions option exercises or new grants and purchases?

The filing shows a new grant of options for 500,000 shares at a $0.00 exercise price, not an exercise of existing options. Separately, he completed an open-market purchase of 1,000,000 common shares at $0.6704 per share, increasing his direct share ownership.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 03/03/2026 - 08:49 AM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Wambeke David J.

(Last) (First) (Middle)

7599 ANAGRAM DRIVE

(Street)

EDEN PRAIRIE MN 55344

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
NEUROONE MEDICAL TECHNOLOGIES Corp [ NMTC ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Business Officer

3. Date of Earliest Transaction (Month/Day/Year)
03/01/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/01/2026		P		1,000,000	A	$0.6704	1,000,000	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Option to Purchase Common Stock	$0.6704	03/01/2026		A		500,000		(1)	02/29/2036	Common Stock	500,000	$0	500,000	D

Explanation of Responses:

1. 25% will vest on March 1, 2027, and the remaining 75% will vest in 12 equal installments on the last day of each quarter beginning on March 31, 2027.

	/s/ Emily Johns, by Power of Attorney	03/03/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.